IVC Filter Lawsuit: Bard Settled, Cook Still Litigating

An IVC filter is meant to be a temporary safeguard — implanted to catch blood clots, and in many cases removed once the danger passes. For a documented share of patients, neither part of that plan worked as intended: the device itself sometimes failed, and the “temporary” often quietly became permanent.

Quick answer: IVC filter lawsuits allege devices from C.R. Bard and Cook Medical were defectively designed, prone to fracture, migration, tilting, or perforating the vein wall. Bard’s litigation (MDL No. 2641, District of Arizona) has largely resolved through confidential settlements covering over 8,600 cases. Cook’s litigation (MDL No. 2570, Southern District of Indiana) remains active, with a mixed bellwether record — Cook won the first trial, then lost the next two for $1.2 million and $3 million — and settlement conferences only beginning in 2026. Separately, the FDA has found that 70–80% of patients with a “retrievable” filter never have it removed, raising a distinct follow-up-failure question alongside the product-defect claim.

What an IVC Filter Does, and What the Lawsuits Allege

An inferior vena cava (IVC) filter is a small device implanted in the body’s largest vein to catch blood clots before they can travel to the lungs and cause a pulmonary embolism — typically used for patients who cannot safely take blood-thinning medication. Many models are designed to be retrievable, meant to be removed once the underlying clot risk has passed.

Lawsuits allege that certain retrievable models — most prominently from C.R. Bard and Cook Medical — were defectively designed in ways that made them prone to fracture, migrate, tilt, or perforate the vein wall, and that the manufacturers failed to adequately warn physicians and patients about these risks. The FDA reported more than 900 adverse events associated with these devices as early as 2010, including migration, fracture, embolization of broken fragments, and vein perforation.

Two Manufacturers, Two Very Different Outcomes So Far

As with several mass torts covered on this site, there is no single IVC filter case — see our explainer on how mass tort litigation actually works for what that structure generally means. Here, two manufacturers have run two entirely separate federal dockets:

• C.R. Bard — centralized as MDL No. 2641, In re: Bard IVC Filters Products Liability Litigation, in the U.S. District Court for the District of Arizona. After an early bellwether trial produced a $3.6 million verdict against Bard over its G2 filter — which had fractured, tilted and migrated, perforating the vein — the litigation moved toward resolution. It has now largely settled through confidential agreements covering more than 8,600 cases.
• Cook Medical — a separate proceeding, MDL No. 2570, in the U.S. District Court for the Southern District of Indiana, before Senior Judge Richard L. Young. This docket remains active, with thousands of cases still pending as of 2026.

Two manufacturers is a manageable split. See our guide to the Zantac ranitidine cancer litigation for a mass tort split across four different companies and two separate court systems at once, each in a genuinely different posture — from a funded multibillion-dollar settlement to an outright dismissal of over 80,000 cases.

Bard: Resolved, But Confidentially

Because Bard’s resolution proceeded through confidential settlements rather than a single published fund, there is no headline dollar figure describing what an individual case was worth — a genuinely different situation from a docket where a global settlement amount is publicly disclosed. If your claim was against Bard specifically, confirming your own case’s status directly with your attorney or the relevant claims administrator is the only reliable way to know where it actually stands.

Cook Medical: A Mixed Bellwether Record, Now Moving Toward Settlement

Cook’s litigation illustrates why a single bellwether result doesn’t resolve an entire mass tort. Cook won the first bellwether trial in November 2017 — but then lost the next two, with juries awarding $1.2 million and $3 million to the respective plaintiffs. Rather than a global settlement announcement, this docket has moved more gradually: as of 2026, settlement conferences have begun for at least some pending cases, and more than 1,000 cases have been resolved through settlement or dismissal since January 2025 — a mature MDL working through its docket case by case rather than through one consolidated resolution.

A Second, Separate Question: Was the Filter Ever Removed?

This is worth understanding as its own issue, distinct from whether the device itself was defective. Because many IVC filters are designed to be retrievable rather than permanent, the FDA has specifically studied what happens to patients after implantation — and found a genuinely striking pattern. In a May 2014 safety communication, the FDA noted that the risk-benefit balance for many patients shifts toward removal roughly 29 to 54 days after implantation, once the transient clot risk has passed. Despite that, the agency has found that an estimated 70% to 80% of patients with a retrievable filter never return to have it removed at all.

That gap matters legally as well as medically. A product liability claim against the manufacturer addresses whether the device itself was defectively designed. A separate claim — potentially against the implanting physician or health system rather than the manufacturer — can exist where a patient was never adequately informed that the filter needed follow-up removal, or where a provider failed to track a retrievable filter that should have been removed. These are genuinely distinct claims against potentially different defendants, and a single patient’s situation can raise one, the other, or both.

A Different Bard Device Facing a Similar Allegation

The fracture-and-migration theory behind this litigation isn’t unique to IVC filters within the same corporate family. See our guide to the Bard PowerPort litigation for a separate, entirely distinct mass tort alleging that a different implanted Bard device — a port catheter used for chemotherapy and other long-term IV access — fractures due to a different material defect. That litigation remains at the early bellwether-trial stage, a genuinely different posture from how thoroughly Bard’s IVC filter litigation has already resolved.

Evidence That Actually Matters

• Implant records identifying the specific filter model and manufacturer — essential, since Bard’s and Cook’s litigation postures are entirely different
• Imaging showing the filter’s current position, or any fracture, tilt or migration
• Records of any attempted or completed retrieval procedure, or the absence of one
• Documentation of the complication itself — a new pulmonary embolism, vein perforation, or symptoms that led to the filter’s discovery, sometimes years after implantation
• What the patient and subsequent treating providers were actually told about the need for follow-up removal, where a failure-to-retrieve theory is involved

Practical Steps

1. Identify the exact filter model and manufacturer from your implant records, since Bard and Cook are in entirely different procedural postures.
2. Confirm whether the filter was ever removed, and if not, why — this can raise a separate question from the product-defect claim itself.
3. Gather imaging and records documenting any complication, including fracture, migration, or perforation.
4. If your claim is against Bard, confirm your specific case’s status directly given the confidential nature of that resolution.
5. If your claim is against Cook, understand that settlement conferences are still ongoing rather than a completed, global resolution.
6. Consult an attorney handling IVC filter claims specifically, given how differently the two manufacturers’ dockets are postured and how the product-defect and failure-to-retrieve theories can each apply.

Sources & Further Reading

• U.S. District Court, District of Arizona — docket for MDL No. 2641, In re: Bard IVC Filters Products Liability Litigation
• U.S. District Court, Southern District of Indiana — docket for MDL No. 2570, the Cook Medical IVC filter litigation
• U.S. Food and Drug Administration — 2010 initial safety communication and May 7, 2014 updated safety communication on removal of retrievable IVC filters, including the 70–80% non-retrieval finding
• See our guides to defective product claims and the three liability theories for the design-defect framework this litigation is built on, how mass tort litigation actually works for how an MDL and a bellwether trial function generally, and the four elements of a medical malpractice claim for the separate standard-of-care framework a failure-to-retrieve claim against a physician or hospital would be built on